Analyst Consensus ?
ConsensusHold39 ratings
Bullish1538.4%
Neutral2359.0%
Bearish12.6%
1 unmapped firm rating excluded from the percentages.
Pfizer Inc. · PFE · FY2024 Q4 · Calendar Q1 2025
Pfizer Maintains Guidance While Advancing Oncology and Vaccine Pipeline
Pfizer's maintained guidance, oncology and vaccine pipeline progress, cost savings and commercial execution support a constructive operating case; the evidence is tempered by pricing reform, regulatory, competitive and COVID-19 demand risks.
Reported Before market openNYSEHealthcare
$171.16B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $0.48
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $17.28B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-1.3%
Event window
SPY move
+0.7%
Same window
Abnormal move
-1.9%
Stock minus SPY
Volume
1.9×
Versus trailing sessions
Subsequent drift
+0.3%
Up to 20 sessions
PFESPY benchmark
Ask FN2 about PFE FY2024 Q4
Transcript, numbers and history already loaded
What drove PFE's -1.3% move after FY2024 Q4 earnings?What changed in PFE's guidance and outlook in FY2024 Q4?Give me the bull and bear case for PFE after FY2024 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, management moved from raised full-year 2024 guidance to maintained 2025 guidance, while sharpening focus on Seagen-enabled oncology, vaccine pipeline expansion, cost realignment, deleveraging and AI-enabled commercial execution.
Guidance delta
Management maintained 2025 guidance at $61-$64 billion of revenue and $2.80-$3.00 of adjusted EPS.
Key takeaways
- Management described 2024 revenue of $63.6 billion and adjusted EPS of $3.11, with full-year margin expansion to 74%.
- The company emphasized oncology pipeline milestones, vaccine expansion and AI-enabled commercial execution.
- Cost realignment targets $4.5 billion of net savings by 2025, alongside a goal of 3.25x gross leverage by year-end 2025.
- Management outlined Phase 3 work for PCV-25, a preclinical PCV-30 program and continued development of metabolic candidates.
Management priorities
- Advance oncology pipeline milestones and regulatory decisions.
- Launch Phase 3 studies for PCV-25 and continue the preclinical PCV-30 program.
- Deliver the cost-savings program and pursue deleveraging.
- Expand AI-enabled commercial platforms and global field resource deployment.
- Evaluate business-development opportunities and monetize the remaining Haleon stake.
Follow PFE with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$30.03Current
$20Low
$39.14Average
$70High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 25, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| JP Morgan | Neutral | Neutral | Maintain | Oct 9, 2026 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Oct 8, 2026 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | Oct 6, 2026 |
| HSBC | Hold | Hold | Maintain | Sep 10, 2026 |
| Guggenheim | Buy | Buy | Maintain | Aug 7, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Jul 13, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Jul 10, 2026 |
| RBC Capital | Sector Perform | Underperform | Upgrade | Jun 10, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Apr 29, 2026 |
| UBS | Neutral | Neutral | Maintain | Apr 13, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Apr 10, 2026 |
| Argus Research | Buy | Hold | Upgrade | Mar 2, 2026 |
| Freedom Broker | Buy | Buy | Maintain | Feb 9, 2026 |
| Goldman Sachs | Neutral | Buy | Downgrade | Apr 8, 2025 |
| Truist Securities | Buy | Buy | Maintain | Dec 18, 2024 |
| Daiwa Capital | Outperform | Neutral | Upgrade | Aug 8, 2024 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 31, 2024 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 31, 2024 |
| TD Cowen | Market Perform | Outperform | Downgrade | Jan 4, 2024 |
| Jefferies | Buy | Hold | Upgrade | Oct 16, 2023 |
| Credit Suisse | Neutral | Outperform | Downgrade | Jun 29, 2023 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Feb 1, 2023 |
| Atlantic Equities | Neutral | Neutral | Maintain | Feb 1, 2023 |
| Mizuho | Neutral | Neutral | Maintain | Dec 14, 2021 |
| DZ Bank | Buy | Hold | Upgrade | Feb 4, 2021 |
| Bernstein | Perform | Market Perform | Maintain | Nov 10, 2020 |
| Berenberg | Hold | Hold | Maintain | Sep 29, 2020 |
| Bank of America | Neutral | Buy | Downgrade | Jul 30, 2019 |
| Argus | Outperform | Neutral | Upgrade | Jan 31, 2019 |
| Leerink Swann | Market Perform | Market Perform | Maintain | Jan 31, 2018 |
| Societe Generale | Hold | Hold | Maintain | Apr 6, 2016 |
| SunTrust Robinson Humphrey | Neutral | Neutral | Maintain | Feb 16, 2016 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Oct 20, 2015 |
| PiperJaffray | Overweight | Overweight | Maintain | Jun 17, 2015 |
| Deutsche Bank | Buy | Buy | Maintain | Apr 28, 2015 |
| LBBW Research | Buy | Hold | Upgrade | Nov 14, 2013 |
| Standpoint Research | Sell | Hold | Downgrade | Jul 2, 2013 |
| Hilliard Lyons | Long Term Buy | Maintain | Jan 29, 2013 | |
| MKM Partners | Neutral | Buy | Downgrade | Nov 27, 2012 |
| ISI Group | Buy | Buy | Maintain | Apr 9, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $30.03. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Cantor Fitzgerald | Carter Gould | $28 | $28 | -6.8% | Oct 8, 2026 |
| Scotiabank | Analyst unavailable | $33 | $27.3 | +9.9% | Oct 6, 2026 |
| HSBC | Analyst unavailable | $30 | $27.78 | -0.1% | Sep 10, 2026 |
| Guggenheim | Analyst unavailable | $31 | $26.2 | +3.2% | Aug 7, 2026 |
| HSBC | Analyst unavailable | $28 | $24.32 | -6.8% | Jul 6, 2026 |
| UBS | Michael Yee | $27 | $26.34 | -10.1% | May 27, 2026 |
| Wolfe Research | Alexandria Hammond | $26 | $25.96 | -13.4% | May 14, 2026 |
| Morgan Stanley | Terence Flynn | $27 | $27.06 | -10.1% | Mar 17, 2026 |
| BMO Capital | Evan David Seigerman | $30 | $26.48 | -0.1% | Mar 9, 2026 |
| RBC Capital | Trung Huynh | $25 | $27.14 | -16.7% | Feb 24, 2026 |
| Barclays | Emily Field | $25 | $26.86 | -16.7% | Feb 19, 2026 |
| Daiwa | Narumi Nakagiri | $27 | $27.73 | -10.1% | Feb 12, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $27 | $25.88 | -10.1% | Jan 27, 2026 |
| UBS | Analyst unavailable | $25 | $25.43 | -16.7% | Jan 6, 2026 |
| Wolfe Research | Alexandria Hammond | $24 | $25.53 | -20.1% | Dec 17, 2025 |
| Morgan Stanley | Analyst unavailable | $28 | $25.89 | -6.8% | Dec 12, 2025 |
| HSBC | Rajesh Kumar | $29 | $25.33 | -3.4% | Dec 10, 2025 |
| Guggenheim | Analyst unavailable | $35 | $25.17 | +16.6% | Nov 24, 2025 |
| Goldman Sachs | Asad Haider | $26 | $24.22 | -13.4% | Nov 5, 2025 |
| Bernstein | Courtney Breen | $30 | $24.45 | -0.1% | Oct 31, 2025 |
| Morgan Stanley | Analyst unavailable | $32 | $25.24 | +6.6% | Oct 10, 2025 |
| UBS | Tim Anderson | $28 | $27.16 | -6.8% | Oct 1, 2025 |
| Cantor Fitzgerald | Carter Gould | $24 | $22.53 | -20.1% | Apr 22, 2025 |
| Truist Financial | Robyn Karnauskas | $32 | $25.89 | +6.6% | Dec 18, 2024 |
| Goldman Sachs | Chris Shibutani | $33 | $28.46 | +9.9% | Oct 30, 2024 |
| Bernstein | Courtney Breen | $32 | $29.67 | +6.6% | Oct 17, 2024 |
| Barclays | Carter Gould | $32 | $28.93 | +6.6% | Sep 25, 2024 |
| Daiwa | Narumi Nakagiri | $34 | $28.85 | +13.2% | Aug 7, 2024 |
| Wells Fargo | Mohit Bansal | $30 | $31.39 | -0.1% | Jul 31, 2024 |
| Goldman Sachs | Chris Shibutani | $34 | $31.39 | +13.2% | Jul 31, 2024 |
| Guggenheim | Vamil Divan | $36 | $30.72 | +19.9% | Jul 30, 2024 |
| Barclays | Carter Gould | $30 | $27.72 | -0.1% | Jul 10, 2024 |
| BMO Capital | Evan Seigerman | $36 | $29.6 | +19.9% | May 22, 2024 |
| Cantor Fitzgerald | Louise Chen | $45 | $26.97 | +49.9% | Feb 14, 2024 |
| Morgan Stanley | Thomas Yeh | $20 | $26.92 | -33.4% | Dec 14, 2023 |
| Morgan Stanley | Terence Flynn | $37 | $30.5 | +23.2% | Nov 27, 2023 |
| Morgan Stanley | Analyst unavailable | $45 | $43.84 | +49.9% | Feb 1, 2023 |
| Credit Suisse | Analyst unavailable | $50 | $43.59 | +66.5% | Feb 1, 2023 |
| Barclays | Analyst unavailable | $44 | $44.16 | +46.5% | Feb 1, 2023 |
| Atlantic Equities | Analyst unavailable | $46 | $44.16 | +53.2% | Feb 1, 2023 |
| Leerink Partners | Analyst unavailable | $48 | $44.16 | +59.8% | Feb 1, 2023 |
| Morgan Stanley | Analyst unavailable | $53 | $54.73 | +76.5% | Dec 14, 2022 |
| Goldman Sachs | Chris Shibutani | $60 | $53.37 | +99.8% | Dec 13, 2022 |
| Credit Suisse | Analyst unavailable | $55 | $48.33 | +83.2% | Nov 18, 2022 |
| Leerink Partners | David Risinger | $55 | $52.88 | +83.2% | May 23, 2022 |
| Wells Fargo | Mohit Bansal | $54.42 | $19.11 | +81.2% | May 10, 2022 |
| Wells Fargo | Mohit Bansal | $55 | $49.04 | +83.2% | May 9, 2022 |
| Morgan Stanley | Analyst unavailable | $52 | $49.68 | +73.2% | May 4, 2022 |
| Mizuho Securities | Vamil Divan | $55 | $49.07 | +83.2% | May 2, 2022 |
| Cantor Fitzgerald | Louise Chen | $75 | $53.12 | +149.8% | Apr 15, 2022 |
| Morgan Stanley | Terrance Flynn | $55 | $55.17 | +83.2% | Apr 10, 2022 |
| Citigroup | Andrew Baum | $57 | $55.17 | +89.8% | Apr 9, 2022 |
| Bank of America Securities | Geoff Meacham | $70 | $50.27 | +133.1% | Mar 12, 2022 |
| Barclays | Carter Gould | $54 | $51.7 | +79.8% | Feb 8, 2022 |
| Goldman Sachs | Chris Shibutani | $50 | $51.7 | +66.5% | Feb 8, 2022 |
| J.P. Morgan | Chris Schott | $57 | $51.7 | +89.8% | Feb 8, 2022 |
| BMO Capital | Evan Seigerman | $76 | $54.95 | +153.1% | Jan 15, 2022 |
| Bernstein | Aaron Gal | $65 | $56.22 | +116.5% | Jan 3, 2022 |
| Leerink Partners | Geoff Porges | $56 | $59.1 | +86.5% | Dec 22, 2021 |
| UBS | Colin Bristow | $60 | $54.78 | +99.8% | Dec 13, 2021 |
| Independent Research | Tobias Gottschalt | $54 | $49.8 | +79.8% | Nov 11, 2021 |
| Wolfe Research | Tim Anderson | $46 | $44.09 | +53.2% | Nov 3, 2021 |
| RBC Capital | Daniel Busby | $44 | $42.1 | +46.5% | Jul 29, 2021 |
| Argus Research | David Toung | $55 | $37.54 | +83.2% | Jun 1, 2021 |
Track every rating change on PFE the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationPfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid.…
Historical context
All PFE earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Limited | FY2027 Q2 · Calendar Q4 2026 | +24.0% | -0.2% | Dr. Reddy’s: margins improve as semaglutide rollout advances |
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| ARGX argenx SE | FY2026 Q3 · Calendar Q4 2026 | — | -1.6% | argenx: VYVGART momentum and a broader late-stage pipeline |
| MEDP Medpace Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | +9.0% | -1.3% | Medpace: Record awards lift backlog as 2026 outlook improves |
| MOH Molina Healthcare, Inc. | FY2026 Q3 · Calendar Q4 2026 | +12.7% | +0.8% | Molina reaffirms 2026 outlook as Florida contract scales |
Latest beats and misses
Who reports nextBeat on EPS
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- RDYFY2027 Q2 · October 23, 2026+24.0% EPS-0.2% move
- SLBFY2026 Q3 · October 23, 2026+3.7% EPS+7.1% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the PFE recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-01-21T00:01:13.267231+00:00
- Polygon adjusted daily market bars · 2026-10-25T04:00:45.317920+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-25T04:00:45.315714+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-25. For educational purposes only; not investment advice.